 | • レポートコード：MRC2203A275 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のコンピュテーショナルバイオロジー市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、用途別（細胞・生物学的シミュレーション、創薬・疾患モデリング、前臨床医薬品開発、臨床試験、人体シミュレーションソフトウェア）分析、ツール別（データベース、インフラストラクチャ（ハードウェア）、分析ソフトウェア・サービス）分析、サービス別（社内、契約）分析、エンドユーザー別（学術、工業・商業）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のコンピュテーショナルバイオロジー市場規模：用途別（細胞・生物学的シミュレーション、創薬・疾患モデリング、前臨床医薬品開発、臨床試験、人体シミュレーションソフトウェア） ・世界のコンピュテーショナルバイオロジー市場規模：ツール別（データベース、インフラストラクチャ（ハードウェア）、分析ソフトウェア・サービス） ・世界のコンピュテーショナルバイオロジー市場規模：サービス別（社内、契約） ・世界のコンピュテーショナルバイオロジー市場規模：エンドユーザー別（学術、工業・商業） ・世界のコンピュテーショナルバイオロジー市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Dassault Systèmes SE、Certara、Chemical Computing Group ULC、…） ・市場機会・将来傾向 |
The global computational biology market is expected to grow with a CAGR of 19.27%. Factors that are responsible for the growth of the market include increase in bioinformatics research, increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and growth of drug designing and disease modeling.
Bioinformatics is recognized as part of the essential knowledge base of numerous career paths in biomedical research and healthcare. The field of bioinformatics and computational biology has gone through a number of transformations over the past 15 years, establishing itself as a key component of new biology. The use of bioinformatics tools in life sciences has become necessary to analyze experimental data. The huge amounts of data pose a challenge for the biological community, as most biologists are not familiar with informatics and statistical interpretation. An interdisciplinary collaboration was started with an aim to address the need for biologists to understand biological data.
Recent improvements in bioinformatics include capacity-building through activities, such as research funding and training opportunities. Increased funding in bioinformatics is helping in creating more advancements in the field of computational biology.
Key Market Trends
Industry and Commercials Sub-segment is Expected to hold its Highest Market Share in the End User Segment
In the end user segment of the market, the Industry and Commercials sub-segment is believed to have the largest market size and is expected to witness a CAGR of 19.50% during the forecast period.
Computational biology has a wide range of applications in the fields of genomics, proteomics, pharmacogenomics, and drug discovery. For drug discovery and clinical trials, many companies approach third-party services, who have to maintain computational biology setups for carrying out various drug discovery processes. Many third-party services and small laboratories that maintain computational biology setups are expected to gain huge profits, as they successfully reduce the overall time needed for drug discovery and various other scientific experiments.
The software and databases are relatively costlier, and the cost of drug discovery processes vary across countries, which makes many industries opt for outsourcing, thereby, leading to an increased demand for small laboratories and other commercial companies. Hence, with the increase in bioinformatics research, the increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and the growth of drug designing, disease modeling, and personalized medicine, the demand for computational biology for industry and commercial purposes is expected to increase, thereby, driving the market during the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for computational biology and is expected to continue its stronghold for a few more years. The United States is the leading nation in the field of synthetic biology, which is an emerging discipline involving the creation, control, and reprogramming of biological systems. Since 2005, the US government has channelled more than USD 1 billion for the development of computational biology and synthetic biology. The annual average expenditure for the development of computational biology, by the United States government, has been estimated to be USD 140 million.
The overall market for computational biology in the United States is scheduled to grow manifold, over the forecast period, primarily due to high expenditure in drug development endeavors (highest in the world).
Competitive Landscape
The computational biology market is expected to become highly competitive in the near future, as it consists of several major players. With increasing technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices. Companies, like Dassault Systèmes, Chemical Computing Group Inc., Instem Plc. (Leadscope Inc.), Compugen Ltd, and Certara, hold substantial shares in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Bioinformatics Research
4.2.2 Increasing Number of Clinical Studies in Pharmacogenomics and Pharmacokinetics
4.2.3 Growth of Drug Designing and Disease Modeling
4.3 Market Restraints
4.3.1 Lack of Trained Professionals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Cellular and Biological Simulation
5.1.1.1 Computational Genomics
5.1.1.2 Computational Proteomics
5.1.1.3 Pharmacogenomics
5.1.1.4 Other Cellular and Biological Simulations (Transcriptomics/Metabolomics)
5.1.2 Drug Discovery and Disease Modelling
5.1.2.1 Target Identification
5.1.2.2 Target Validation
5.1.2.3 Lead Discovery
5.1.2.4 Lead Optimization
5.1.3 Preclinical Drug Development
5.1.3.1 Pharmacokinetics
5.1.3.2 Pharmacodynamics
5.1.4 Clinical Trials
5.1.4.1 Phase I
5.1.4.2 Phase II
5.1.4.3 Phase III
5.1.5 Human Body Simulation Software
5.2 By Tool
5.2.1 Databases
5.2.2 Infrastructure (Hardware)
5.2.3 Analysis Software and Services
5.3 By Service
5.3.1 In-house
5.3.2 Contract
5.4 By End User
5.4.1 Academics
5.4.2 Industry and Commercials
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Dassault Systèmes SE
6.1.2 Certara
6.1.3 Chemical Computing Group ULC
6.1.4 Compugen Ltd
6.1.5 Rosa & Co. LLC
6.1.6 Genedata AG
6.1.7 Insilico Biotechnology AG
6.1.8 Instem Plc. (Leadscope Inc.)
6.1.9 Nimbus Discovery LLC
6.1.10 Strand Life Sciences
6.1.11 Schrodinger
6.1.12 Simulation Plus Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS